Round window membrane delivery of L-methionine provides protection from cisplatin ototoxicity without compromising chemotherapeutic efficacy.

[1]  L. Hughes,et al.  D-Methionine protects against cisplatin damage to the stria vascularis , 1999, Hearing Research.

[2]  J. Arezzo,et al.  L- and D- methionine provide equivalent long term protection against CDDP-induced ototoxicity in vivo, with partial in vitro and in vivo retention of antineoplastic activity. , 1999, Neurotoxicology.

[3]  Y. Raphael,et al.  The influence of interleukin-1 receptor antagonist transgene on spiral ganglion neurons , 1999, Hearing Research.

[4]  L. Rybak,et al.  Effect of 4-methylthiobenzoic acid on cisplatin-induced ototoxicity in the rat 1 Part of this material was presented at the twenty-first Midwinter Research Meeting of the Association for Research in Otolaryngology, St. Petersburg Beach, FL, 15–19 February 1998. 1 , 1999, Hearing Research.

[5]  E. Neuwelt,et al.  First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate. , 1998, The Journal of pharmacology and experimental therapeutics.

[6]  J. Segall,et al.  Cell motility of tumor cells visualized in living intact primary tumors using green fluorescent protein. , 1998, Cancer research.

[7]  W. Liu,et al.  Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. , 1997, The American journal of otology.

[8]  B. Malgrange,et al.  Protection of both auditory hair cells and auditory neurons from cisplatin induced damage. , 1997, Acta oto-laryngologica.

[9]  L. Hughes,et al.  d-Methionine provides excellent protection from cisplatin ototoxicity in the rat , 1996, Hearing Research.

[10]  D. Butterfield,et al.  Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants , 1996, Hearing Research.

[11]  J. Glick,et al.  Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B Malgrange,et al.  NT‐3 and/or BDNF therapy prevents loss of auditory neurons following loss of hair cells , 1996, Neuroreport.

[13]  L. Rybak,et al.  Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: antioxidant system. , 1995, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[14]  W. J. Clerici,et al.  Direct effects of reactive oxygen species on cochlear outer hair cell shape in vitro , 1995, Hearing Research.

[15]  B. Blakley,et al.  Risk factors for ototoxicity due to cisplatin. , 1994, Archives of otolaryngology--head & neck surgery.

[16]  M. Ryan,et al.  The nephrotoxicity, cytotoxicity and renal handling of a cisplatin-methionine complex in male Wistar rats. , 1994, Toxicology.

[17]  Alfred L. Nuttall,et al.  Osmotic pump implant for chronic infusion of drugs into the inner ear , 1993, Hearing Research.

[18]  V. Schweitzer.  Ototoxicity of chemotherapeutic agents. , 1993, Otolaryngologic clinics of North America.

[19]  R. Fram.  Cisplatin and platinum analogues: recent advances , 1992, Current opinion in oncology.

[20]  D. Bagger-sjöbäck,et al.  Dose-dependent inner ear changes after i.v. administration of cisplatin. , 1991, The Journal of otolaryngology.

[21]  A. Katsarkas,et al.  Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration. , 1991, Ear and hearing.

[22]  S. Tognella.  Pharmacological interventions to reduce platinum-induced toxicity. , 1990, Cancer treatment reviews.

[23]  G. Laurell,et al.  High‐Dose cisplatin treatment: Hearing loss and plasma concentrations , 1990, The Laryngoscope.

[24]  M. Jones,et al.  L-methionine antagonism of cis-platinum nephrotoxicity. , 1990, Toxicology and applied pharmacology.

[25]  Jones Mm,et al.  Thiol and thioether suppression of cis-platinum-induced nephrotoxicity in rats bearing the Walker 256 carcinosarcoma. , 1989 .

[26]  A. Ardizzoni,et al.  Oral chemotherapy for poor risk small-cell lung cancer patients with combined idarubicin and etoposide. , 1989, Anticancer research.

[27]  E. Fody,et al.  Dithiocarbamate-induced biliary platinum excretion and the control of cis-platinum nephrotoxicity. , 1989, Toxicology and applied pharmacology.

[28]  M. Anniko,et al.  Effects of cisplatin and thiosulfate upon auditory brainstem responses of guinea pigs , 1988, Hearing Research.

[29]  P. Schachern,et al.  Experimental studies on round window structure: Function and permeability , 1988, The Laryngoscope.

[30]  S. Aamdal,et al.  Some procedures to reduce cis-platinum toxicity reduce antitumour activity. , 1987, Cancer treatment reviews.

[31]  M. Maines.  Differential effect of cis-platinum (cis-diamminedichloroplatinum) on regulation of liver and kidney haem and haemoprotein metabolism. Possible involvement of gamma-glutamyl-cycle enzymes. , 1986, The Biochemical journal.

[32]  R. Golbey,et al.  High dose Cis‐platinum diammine dichloride. Amelioration of renal toxicity by mannitol diuresis , 1977, Cancer.

[33]  M V Goycoolea,et al.  The round window membrane under normal and pathological conditions. , 1992, Acta oto-laryngologica. Supplementum.

[34]  S. Juhn,et al.  Review of round window membrane permeability. , 1989, Acta oto-laryngologica. Supplementum.

[35]  E. Perez,et al.  Evaluation of cisplatin dose intensity: current status and future prospects. , 1989, Anticancer research.

[36]  S. Lippard,et al.  Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. , 1985, Biochimica et biophysica acta.

[37]  Y. Nakai,et al.  Ototoxicity of the anticancer drug cisplatin. An experimental study. , 1982, Acta oto-laryngologica.